Tracking The Origins And Drivers Of Metastasis In Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,022,600.00
Summary
Prostate cancer is now the most commonly diagnosed cancer but only 10% of men with it, will die from it. Our current ability to discriminate between cancers with an indolent course and those that are lethal is poor. This project will examine the mixture of tumour clones (subclones) that are present in prostate cancers and define and track those cancer subclones that break away from the prostate and lodge in distant sites, causing death.
Determining The Origin Of Lethal Metastases In Multifocal Primary Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$696,470.00
Summary
New biomarkers are required to accurately predict lethal prostate cancer from benign, indolent disaese that doesn't require expensive treatment. To do this relies on finding molecular differences between disease states. Advancements in high throughput genomic technologies enables us to now probe the lethal prostate cancer genome and transcriptome and distinguish this disease state from other forms of prostate cancer.
Metagenomic Analysis To Determine The Prostate Microenvironment And The Aetiology Of Inflammatory Mediated Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$339,534.00
Summary
Infectious organisms have been implicated in the development of several different malignancies. This project aims to determine if this may also be applicable in prostate cancer and if so, to define which organism/s may be responsible, thus providing targets for improving diagnosis, treatment and prevention strategies. The approach will be to identify DNA in the prostate tumour tissue that is foreign to the �normal� prostate environment and indicative of an invading organism.
Kallikrein Gene Variants In Prostate Cancer: In-depth Association And Functional Studies
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
The number of men diagnosed with prostate cancer varies substantially between races, indicating a role of genetics in prostate cancer development. Recently, genetic variations in the PSA gene have been related to prostate cancer risk. I aim to elucidate the molecular mechanism of this correlation and to systematically investigate the association of other novel genetic variations in PSA and related genes with prostate cancer risk in a search of sensitive clinical biomarkers for prostate cancer di ....The number of men diagnosed with prostate cancer varies substantially between races, indicating a role of genetics in prostate cancer development. Recently, genetic variations in the PSA gene have been related to prostate cancer risk. I aim to elucidate the molecular mechanism of this correlation and to systematically investigate the association of other novel genetic variations in PSA and related genes with prostate cancer risk in a search of sensitive clinical biomarkers for prostate cancer diagnosis and prognosis.Read moreRead less